PubGrade’s platform-as-a-service solution PubGrade for Publishers provided Cell Press with a fully integrated advertising platform that enables the sales team to offer their advertising clients a cutting edge digital advertising solution.
Jonathan Christison, VP, Commercial Development, Elsevier Pharma and Life Science Solutions commented: “We were extremely excited for PubGrade to integrate with the cell.com platform at the beginning of Q2, and our experience has surpassed our expectations. It can be challenging to successfully develop digital marketing solutions that serve the acute and stringent needs of our biotechnology clientele. The team at PubGrade differentiated themselves from the field with their experience in this sector, and their deep understanding of the researcher’s information consumption. PubGrade addresses the obvious need for us to be able to offer our clients a contextually targeted solution that provides a high ROI, and allows their advertisements to be positioned adjacent to Cell Press’ leading life science content in order to assist and inform researchers about the latest tools and developments to drive their research at the bench. We’ve seen tremendous metrics and researcher engagement through our time with PubGrade, and are excited to make it a central part of our marketing solution offering as we move through these prohibitive times when face-to-face interaction is challenging.”
John Michael, PubGrade’s Commercial Director added; “Our platform continues to perform exceptionally well in helping Publishers to work with their advertisers across multiple highly specialised scientific research areas. We look forward to continuing to work with Jonathan’s team in helping them to enhance their digital ad offering to their multiple advertisers. This platform offers Cell Press a more efficient workflow process that facilitates enhanced campaign performance ROI and greater reporting transparency for their advertisers, via direct targeting access into the full-text of scientific research published at their site.”
